WestChina-Frontier has established the immunogenicity and immunotoxicity study system to provide the biopharmaceutical industry with all-round testing service covering the entire pre-clinical development cycle of new drugs. The system is dedicated to the development and evaluation of cell therapy, gene therapy and other high-end biological therapy products. The study team consists of multidisciplinary members of medical immunology, cell biology, and molecular biology. Our technology platforms cover immunochemistry, immunohistochemistry, ELISA, MSD, liquid protein chip, ELISPOT, ADCC/CDC; at WestChina-Frontier, design of experiment (DoE) follows applicable NMPA/FDA/OECD/ICH guidelines in order to meet the submission requirements for GLP-compliant studies. We can test biological drugs including cells, antibodies, recombinant proteins, peptides, antibody/peptide conjugates, siRNA and vaccines for their immunogenicity and immunotoxicity.